Stocks · News reference

Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE".

Sep 18, 2026, 7:58 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 14, 2026, 12:06 PMBenzinga Newsdesk
Vyome Holdings Appoints Jerry Leonard As CFO, Succeeding Robert Dickey IV, Who Served As Interim CFO Since August 2025
Finance executive with more than 25 years of experience brings extensive expertise in public company financial management, SEC reporting, financial operations, and governanceVyome Holdings, Inc. (NASDAQ:HIND)
HIND
BenzingaSep 3, 2026, 11:56 AMBenzinga Newsdesk
Chardan Capital Initiates Coverage On Vyome Holdings with Buy Rating, Announces Price Target of $3.5
Chardan Capital analyst Keay Nakae initiates coverage on Vyome Holdings (NASDAQ:HIND) with a Buy rating and announces Price Target of $3.5.
HIND
BenzingaAug 28, 2026, 8:40 PMBenzinga Newsdesk
Vyome Appoints Jerry Leonard As CFO On August 27, 2026
On August 27, 2026, the board of directors (the "Board") of Vyome Holdings, Inc. (the "Company") appointed Jerry Leonard as the Company’s Chief Financial Officer. In connection with Mr. Leonard’s
HIND